Analyst firms · Wells Fargo · VRDN
Wells Fargo VRDN price target and rating history
Viridian Therapeutics Inc. (VRDN) · Health Care
Wells Fargo rates Viridian Therapeutics Inc. (VRDN) Overweight with a $31 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on VRDN since April 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a VRDN price target in the last 12 months, the median target is $47. Wells Fargo's $31 is 34% below that.
- Current rating
- Overweight
- Price target
- $31
- Median target, all firms
- $47
- Actions on VRDN
- 3
Wells Fargo price target on VRDN
Every Wells Fargo rating on VRDN
- Jun 29, 2026
- Dec 19, 2024
- Apr 17, 2023
How other firms rate VRDN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Buy | $47 | Nov 19, 2026 |
| Wells Fargo | Overweight | $31 | Jun 29, 2026 |
| Wedbush | Outperform | $47 | Dec 10, 2025 |
| William Blair | Outperform | Dec 3, 2025 | |
| Truist Securities | Buy | Nov 24, 2025 |
Questions about Wells Fargo and VRDN
- What is Wells Fargo's price target for VRDN?
- Wells Fargo's latest stated price target for Viridian Therapeutics Inc. (VRDN) is $31, from its action on Jun 29, 2026.
- What is Wells Fargo's rating on VRDN?
- Wells Fargo rates VRDN Overweight, a bullish rating, as of Jun 29, 2026.
- When did Wells Fargo last change its view on VRDN?
- On Jun 29, 2026, Wells Fargo upgrades to Overweight from Equal Weight, price target $31.
- How does Wells Fargo's VRDN target compare with other analysts?
- Across 3 firms with a VRDN price target in the last 12 months, the median target is $47. Wells Fargo's $31 is 34% below that.
All Wells Fargo ratingsVRDN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.